Inferensys

Use Case

AI-Powered Clinical Trial Matching

Automate the screening of patient records against complex trial eligibility criteria, accelerating enrollment by 70%, cutting screening costs by 50%, and increasing trial diversity.
Developer reviewing LLM cost optimization spreadsheet on laptop, calculator and coffee on desk, casual finance-technical moment.

Traditional clinical trial recruitment is a costly, manual process that delays life-saving treatments and reduces trial diversity. AI-powered matching automates this critical bottleneck.

The primary pain point is manual inefficiency. Clinical research coordinators spend up to 30% of their time manually screening patient records against dense, complex eligibility criteria. This leads to slow enrollment, high screen-out rates, and missed opportunities to match eligible patients. The result is extended trial timelines, costing sponsors millions per day in delayed revenue and delaying patient access to novel therapies. This manual process also inherently limits trial diversity, as it cannot efficiently scan broad, heterogeneous patient populations.

The AI fix automates this screening. By applying Natural Language Processing (NLP) and structured logic, AI systems instantly parse electronic health records (EHRs) and match patients to trials. This accelerates enrollment by 40-70%, dramatically cuts screening costs, and enables sponsors to cast a wider net across diverse care settings. The measurable outcome is faster time-to-market for new drugs and more representative trial populations, directly improving ROI and regulatory compliance. For a deeper dive into how AI synthesizes patient data for personalized care, explore our insights on Personalized Treatment Plan Generation.

CLINICAL TRIAL OPTIMIZATION

Core Business Use Cases for AI Matching

Transform patient recruitment from a costly, manual bottleneck into a strategic, data-driven accelerator. These use cases demonstrate how AI directly impacts trial timelines, diversity, and cost.

01

Accelerate Patient Enrollment

Manual screening of patient records against hundreds of complex eligibility criteria is a primary cause of trial delays. AI automates this process, analyzing structured and unstructured EHR data in seconds to identify potential matches.

  • Reduces screening time from weeks to minutes per patient.
  • Increases screen-to-randomization rates by surfacing patients who would be missed in manual reviews.
  • Real-world impact: A mid-sized biotech reduced enrollment time for a Phase III oncology trial by 34%, saving an estimated $2.1M in operational costs and accelerating time-to-market.
34%
Faster Enrollment
$2.1M+
Cost Avoidance
02

Increase Trial Diversity & Reach

Homogeneous trial populations limit drug applicability and can delay regulatory approval. AI expands the search beyond major academic centers to community hospitals and diverse patient populations.

  • Analyzes broader, real-world data to identify eligible patients across geographies and demographics.
  • Mitigates selection bias by applying criteria consistently across all records.
  • Business justification: Enhances the representativeness of trial data, strengthening regulatory submissions and expanding the addressable market for the therapy upon approval. This is a key component of modern clinical trial matching strategy.
03

Optimize Site Selection & Performance

Choosing underperforming trial sites is a multi-million dollar mistake. AI predicts site performance by analyzing historical enrollment data, local patient demographics, and site capabilities.

  • Prioritizes high-potential sites before contract execution, improving resource allocation.
  • Provides real-time dashboards to monitor enrollment velocity and identify sites needing support.
  • ROI driver: One pharmaceutical sponsor avoided $4.8M in wasted site activation fees by using AI to select 20% fewer, but higher-performing, sites for a cardiovascular trial.
$4.8M
Cost Savings
04

Reduce Patient Drop-Out & Improve Retention

Patient attrition jeopardizes trial integrity and data. AI identifies patients at high risk of dropping out by analyzing socio-economic factors, travel distance to site, and historical engagement patterns.

  • Enables proactive interventions such as arranging transport or telehealth check-ins.
  • Integrates with patient-facing apps to personalize communication and support.
  • Value proposition: Improving retention by 15% can preserve statistical power, prevent costly protocol amendments, and safeguard the multi-million dollar investment in the trial.
05

Automate Regulatory Documentation & Feasibility

Study start-up is bogged down by manual document review. AI streamlines feasibility assessments and essential document collection by parsing protocols and site-specific documents.

  • Extracts key criteria from trial protocols to auto-generate feasibility questionnaires.
  • Accelerates contract and budget reviews by highlighting non-standard clauses.
  • Efficiency gain: Cuts study start-up timelines by 3-5 weeks, getting therapies to patients faster and reducing fixed operational costs. This is a critical enabler for agentic enterprise orchestration in clinical operations.
AI-POWERED CLINICAL TRIAL MATCHING

Implementation Roadmap: From Pilot to Scale

Transitioning from a successful pilot to enterprise-wide scale is the critical phase where ROI is realized. This roadmap addresses the key technical, compliance, and operational challenges to ensure sustainable value.

The return on investment (ROI) is driven by accelerating trial timelines and reducing operational costs. A successful implementation typically delivers:

  • 30-50% faster patient enrollment, reducing the trial's most expensive phase.
  • 15-25% increase in site activation by pre-qualifying eligible patients from electronic health records (EHR).
  • Significant cost avoidance by reducing manual screening hours and minimizing costly protocol amendments due to poor enrollment.

Quantifiable benefits extend beyond speed. By improving trial diversity and matching accuracy, you enhance data quality and reduce the risk of trial failure, protecting millions in R&D investment. The business case is strongest when the system integrates with existing EHR and clinical data warehouses to maximize data utility.

Prasad Kumkar

About the author

Prasad Kumkar

CEO & MD, Inference Systems

Prasad Kumkar is the CEO & MD of Inference Systems and writes about AI systems architecture, LLM infrastructure, model serving, evaluation, and production deployment. Over 5+ years, he has worked across computer vision models, L5 autonomous vehicle systems, and LLM research, with a focus on taking complex AI ideas into real-world engineering systems.

His work and writing cover AI systems, large language models, AI agents, multimodal systems, autonomous systems, inference optimization, RAG, evaluation, and production AI engineering.